Alzheimer Europe's June 2026 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.

We are always happy to receive feedback, or suggestions regarding news items to share.

On 8 June, Alzheimer Europe published a position paper calling for equitable and timely access to lecanemab and donanemab, the first disease-modifying therapies for Alzheimer's disease authorised in the European Union. Developed following consultation with national member associations, the European Working Group of People with Dementia (EWGPWD) and the European Dementia Carers Working Group (EDCWG), the paper sets out five areas of concern and calls for concrete action from governments, health technology assessment (HTA) bodies, manufacturers and the research community.

Alzheimer Europe is pleased to introduce issue 51 of the Dementia in Europe magazine! There has been much valuable work taking place across Europe in the domains of policy, research, culture and care, and we are delighted to showcase these in our magazine.

Alzheimer Europe is pleased to welcome three new member associations, a new Board of Directors for the 2026-2028 term, and to present its 2025 Annual and Financial Report. These are just three of the important outcomes from the organisation's Annual General Meeting (AGM), which took place on 30 June 2026, in Luxembourg. 

As preparations are underway for the next Alzheimer Europe conference in beautiful Dublin, the early bird registration for the event has closed on 30 June, with more than 1,000 delegates already registered, but don't worry, standard registrations will remain open until 26 October!